

**GAZYVA(R) Vials (1,000 mg/40 ml)**Version  
1.3Revision Date:  
01-23-2020Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015**SECTION 1. IDENTIFICATION**

Product name : GAZYVA(R) Vials (1,000 mg/40 ml)

Product code : RO507-2759/F06

Common name(s), syno- : GAZYVA Vials  
nym(s) of the substance GAZYVARO Vials**Manufacturer or supplier's details**

Company name of supplier : Genentech, Inc.

Address : DNA Way 1  
94080 South San Francisco  
CA  
USA

Telephone : 001-(650) 225-1000

E-mail address : info.sds@roche.com

Emergency telephone

Emergency telephone num- : US Chemtrec phone (800)-424-9300  
ber**Recommended use of the chemical and restrictions on use**

Recommended use : Formulated pharmaceutical active substance

Restrictions on use : For professional users only.

**SECTION 2. HAZARDS IDENTIFICATION****GHS classification in accordance with 29 CFR 1910.1200**

Not a hazardous substance or mixture.

**GHS label elements**

Not a hazardous substance or mixture.

**Other hazards**

None known.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Water	7732-18-5	88.032
Trehalose (D+)-, 2H <sub>2</sub> O	6138-23-4	9.08
Obinutuzumab	949142-50-1	2.5
L-Histidine monohydrochloride monohydrate	5934-29-2	0.224
L-Histidine	71-00-1	0.144
Poloxamer 188	691397-13-4	0.02

## GAZYVA(R) Vials (1,000 mg/40 ml)

Version  
1.3

Revision Date:  
01-23-2020

Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

---

### SECTION 4. FIRST AID MEASURES

- General advice : Do not leave the victim unattended.
- If inhaled : Move to fresh air.  
If unconscious, place in recovery position and seek medical advice.  
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.  
Remove contact lenses.  
Protect unharmed eye.  
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.  
Do not give milk or alcoholic beverages.  
Never give anything by mouth to an unconscious person.  
If symptoms persist, call a physician.  
Rinse mouth with water.
- Most important symptoms and effects, both acute and delayed : None known.
- Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

---

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Specific hazards during fire fighting : No information available.
- Hazardous combustion products : In case of fire hazardous decomposition products may be produced such as:  
Carbon oxides  
Nitrogen oxides (NOx)
- Further information : Standard procedure for chemical fires.  
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protection : Refer to protective measures listed in sections 7 and 8.

**GAZYVA(R) Vials (1,000 mg/40 ml)**

Version 1.3                                      Revision Date: 01-23-2020                                      Date of last issue: 06-10-2017  
 Date of first issue: 12-04-2015

tive equipment and emergency procedures

Environmental precautions : Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Wipe up with absorbent material (e.g. cloth, fleece).  
 Keep in suitable, closed containers for disposal.

**SECTION 7. HANDLING AND STORAGE**

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : For personal protection see section 8.  
 Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage : Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions : See label, package insert or internal guidelines

Materials to avoid : No materials to be especially mentioned.

Storage temperature : Protected from heat and light

Further information on storage stability : No decomposition if stored and applied as directed.

**SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Ingredients with workplace control parameters**

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Obinutuzumab	949142-50-1	IOEL	0.01 mg/m <sup>3</sup>	Roche Industrial Hygiene Committee (RIHC)

**Engineering measures** : No data available

**Personal protective equipment**

Respiratory protection : No personal respiratory protective equipment normally required.

Hand protection

Material : Protective gloves

# SAFETY DATA SHEET

## GAZYVA(R) Vials (1,000 mg/40 ml)

Version  
1.3

Revision Date:  
01-23-2020

Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

Remarks : Wear appropriate protective gloves to prevent skin contact.  
Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.

---

### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution, Clear liquid, Sterile liquid

Color : colorless, light brown

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : does not flash

Evaporation rate : No data available

Self-ignition : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : 1.038 g/cm<sup>3</sup>

Solubility(ies)  
Water solubility : completely miscible

Solubility in other solvents : No data available

Partition coefficient: n-octanol/water : No data available

**GAZYVA(R) Vials (1,000 mg/40 ml)**Version  
1.3Revision Date:  
01-23-2020Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

    Viscosity, dynamic : No data available

    Viscosity, kinematic : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created. Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution

Possibility of hazardous reactions : Stable under recommended storage conditions. No hazards to be specially mentioned.

Incompatible materials : No data available

Hazardous decomposition products : No data available

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Acute toxicity**

Not classified based on available information.

**Components:****Obinutuzumab:**

Acute oral toxicity : Remarks: Not bioavailable by oral administration

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

Not classified based on available information.

**GAZYVA(R) Vials (1,000 mg/40 ml)**Version  
1.3Revision Date:  
01-23-2020Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015**Germ cell mutagenicity**

Not classified based on available information.

**Carcinogenicity**

Not classified based on available information.

**IARC** No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.**OSHA** No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.**NTP** No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.**Reproductive toxicity**

Not classified based on available information.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Obinutuzumab:**

Species	:	cynomolgus monkey
NOAEL	:	mg/kg/w, 30
Application Route	:	i.v.
Exposure time	:	13 Weeks
GLP	:	yes
Remarks	:	Subchronic toxicity

**Aspiration toxicity**

Not classified based on available information.

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity**

No data available

**Persistence and degradability****Components:****Obinutuzumab:**

Biodegradability : Result: Globular proteins are generally well biodegradable

**Bioaccumulative potential****Components:****Obinutuzumab:**

**GAZYVA(R) Vials (1,000 mg/40 ml)**Version  
1.3Revision Date:  
01-23-2020Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015Partition coefficient: n-  
octanol/water : Remarks: No data available**Mobility in soil**

No data available

**Other adverse effects****Product:**Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances  
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).**Components:****Obinutuzumab:**

Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

---

**SECTION 13. DISPOSAL CONSIDERATIONS****Disposal methods**

Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
Do not re-use empty containers.

---

**SECTION 14. TRANSPORT INFORMATION****International Regulations****UNRTDG**

Not regulated as a dangerous good

**IATA-DGR**

Not regulated as a dangerous good

**IMDG-Code**

Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**

Not applicable

**Domestic regulation****49 CFR**

Not regulated as a dangerous good

**GAZYVA(R) Vials (1,000 mg/40 ml)**

Version  
1.3

Revision Date:  
01-23-2020

Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

**SECTION 15. REGULATORY INFORMATION**

**EPCRA - Emergency Planning and Community Right-to-Know**

**CERCLA Reportable Quantity**

This material does not contain any components with a CERCLA RQ.

**SARA 304 Extremely Hazardous Substances Reportable Quantity**

This material does not contain any components with a section 304 EHS RQ.

**SARA 302 Extremely Hazardous Substances Threshold Planning Quantity**

Components	CAS-No.	Component TPQ (lbs)
------------	---------	---------------------

**SARA 311/312 Hazards** : No SARA Hazards

**Clean Air Act**

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM Intermediate or Final VOC's (40 CFR 60.489).

**Clean Water Act**

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

**US State Regulations**

**Massachusetts Right To Know**

**Pennsylvania Right To Know**

Water	7732-18-5
Trehalose (D+)-, 2H2O	6138-23-4

**Maine Chemicals of High Concern**

**Vermont Chemicals of High Concern**

**Washington Chemicals of High Concern**

**The ingredients of this product are reported in the following inventories:**

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.

Obinutuzumab

L-Histidine monohydrochloride monohydrate



**GAZYVA(R) Vials (1,000 mg/40 ml)**

Version  
1.3

Revision Date:  
01-23-2020

Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

Poloxamer 188

- AICS : Not in compliance with the inventory
- NZIoC : On the inventory, or in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Substance(s) not listed on TSCA inventory


**TSCA list**

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

**SECTION 16. OTHER INFORMATION**

**NFPA:**



**HMIS® IV:**

<b>HEALTH</b>	/	0
<b>FLAMMABILITY</b>		0
<b>PHYSICAL HAZARD</b>		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "\*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

**Full text of other abbreviations**

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule;

**GAZYVA(R) Vials (1,000 mg/40 ml)**Version  
1.3Revision Date:  
01-23-2020Date of last issue: 06-10-2017  
Date of first issue: 12-04-2015

ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 01-23-2020

The information provided in this Material Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 1810